---
title: "KALA BIO, Inc. (KALA.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/KALA.US.md"
symbol: "KALA.US"
name: "KALA BIO, Inc."
industry: "Biotechnology"
---

# KALA BIO, Inc. (KALA.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.kalarx.com](https://www.kalarx.com) |

## Company Profile

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company’s lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epi...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -9.66 | 446/603 | - | - | - |
| PB | -39.97 | 546/603 | 6.26 | 5.22 | 1.96 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-10-29T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 0 | 0% |
| Hold | 1 | 100% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.38 |

## References

- [Company Overview](https://longbridge.com/en/quote/KALA.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/KALA.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/KALA.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.